The drug was called Xigris, and for a decade it stood as the only FDA-approved treatment for severe sepsis, a condition that kills more than 200,000 Americans every year. Manufactured by Eli Lilly as a recombinant form of human activated protein C, Xigris was approved in November 2001 amid extraordinary controversy. The FDA advisory committee vote was a dead-even 10-to-10 split, with serious concerns about whether a single clinical trial was enough to justify putting a drug with known bleeding risks into the veins of the sickest patients in the hospital. The FDA approved it anyway. Ten years and roughly a billion dollars in sales later, Eli Lilly pulled Xigris from the market worldwide after a confirmatory trial showed it simply did not work. For families navigating dementia care, the Xigris saga matters more than it might seem.
Older adults with cognitive decline are among the most vulnerable to sepsis, particularly when infections from urinary catheters, pneumonia, or pressure wounds escalate into septic shock. When a loved one lands in the ICU with plummeting blood pressure and failing organs, the drugs administered in those first critical hours can mean the difference between survival and death. Understanding which treatments have solid evidence behind them, and which rode a wave of pharmaceutical marketing into widespread use, is not academic. It is deeply personal. This article traces the full controversial history of Xigris, from its rushed approval to its ignominious withdrawal. It also examines two other septic shock treatments with deeply conflicted evidence trails: corticosteroids and vasopressin. Along the way, we look at what a 2011 drug shortage revealed about how fragile ICU care really is, and what recent research through 2025 suggests about where septic shock treatment is heading.
Table of Contents
- What Was the Hospital Drug Given for Septic Shock, and Why Was Its Approval So Controversial?
- How Xigris Failed and What Its Withdrawal Means for ICU Patients Today
- The Decades-Long Steroid Debate in Septic Shock Treatment
- Vasopressin as a Septic Shock Treatment and What Recent Evidence Shows
- What a Drug Shortage Revealed About the Fragility of Septic Shock Care
- Why Dementia Patients Face Elevated Sepsis Risk
- Where Septic Shock Treatment Is Heading
- Conclusion
- Frequently Asked Questions
What Was the Hospital Drug Given for Septic Shock, and Why Was Its Approval So Controversial?
Xigris, known generically as drotrecogin alfa, was a bioengineered version of activated protein C, a naturally occurring substance that helps regulate inflammation and blood clotting. The theory was elegant: sepsis triggers a catastrophic inflammatory cascade that damages blood vessels and organs, and activated protein C could interrupt that spiral. Eli Lilly developed the drug and tested it in a landmark trial called PROWESS, published in 2001, which showed a 6.1 percent absolute reduction in 28-day mortality among patients with severe sepsis. On paper, that was a meaningful number. In a disease that was killing hundreds of thousands of people annually with no approved pharmacological intervention, it looked like a genuine breakthrough. Eli Lilly’s chairman publicly called it “one of our industry’s genuine breakthroughs” and the company projected blockbuster sales of one billion dollars per year. But the cracks were visible from the start. The FDA advisory committee that reviewed the PROWESS data could not reach a majority.
The 10-to-10 vote reflected deep unease about approving a drug based on a single trial, especially one that showed increased serious bleeding events in treated patients. Subsequent trials in specific populations, including children and patients with less severe sepsis, failed to replicate the PROWESS results. Despite this, Xigris remained on the market for a full decade, prescribed to critically ill patients at a cost of approximately $8,000 per treatment course, making it one of the most expensive hospital drugs of its era. Actual annual sales peaked at roughly $200 million, far short of the billion-dollar projections, in part because many intensivists remained skeptical and reluctant to use it. The conflict-of-interest questions only deepened the controversy. Eli Lilly used the same public relations firm, Belsito and Company, both to promote Xigris commercially and to support the Surviving Sepsis Campaign, the influential clinical guidelines initiative that recommended the drug’s use. Critics argued that this arrangement blurred the line between evidence-based medicine and pharmaceutical marketing in ways that put patients at risk. For families of dementia patients who ended up receiving Xigris during an ICU stay, the question of whether that drug was administered because of genuine clinical evidence or because of a well-funded marketing campaign is an uncomfortable one.
How Xigris Failed and What Its Withdrawal Means for ICU Patients Today
The definitive reckoning came in 2011. The PROWESS-SHOCK trial, a large confirmatory study that the FDA had required as a condition of continued approval, showed no survival benefit whatsoever for patients with septic shock treated with Xigris. On October 25, 2011, Eli Lilly issued a worldwide voluntary withdrawal of the drug. The FDA confirmed the decision, and the European Medicines Agency followed suit. After a decade on the market, the only FDA-approved drug for severe sepsis simply ceased to exist. The withdrawal left a gaping hole in sepsis treatment. There was, and still is, no direct pharmacological replacement for what Xigris was supposed to do.
Treatment for septic shock reverted entirely to supportive care: early antibiotics, intravenous fluids, vasopressors to maintain blood pressure, and mechanical ventilation when organs begin to fail. For older adults with dementia, who often cannot communicate early symptoms of infection and may arrive at the hospital with sepsis already well advanced, the absence of a targeted therapy is particularly consequential. However, there is a counterargument worth acknowledging. Given that Xigris carried real bleeding risks and ultimately showed no mortality benefit, its removal may have prevented more harm than it caused. A drug that does not work but does cause bleeding is worse than no drug at all. The Xigris story has become a cautionary tale in critical care medicine, frequently cited in medical education as an example of how a single positive trial, aggressive marketing, and regulatory willingness to approve under uncertainty can combine to put an ineffective and potentially dangerous drug into widespread use. For families making decisions about a loved one’s ICU care, the lesson is worth absorbing: FDA approval does not guarantee that a drug works, and the most expensive option is not necessarily the best one.
The Decades-Long Steroid Debate in Septic Shock Treatment
Corticosteroids, particularly hydrocortisone, have their own tortured history in septic shock that stretches back more than 40 years. In the 1980s, steroids were initially promoted as a treatment for sepsis, only to be abandoned after two large trials concluded they were not beneficial and possibly harmful. Then the pendulum swung again. In 2002, a trial led by Djillali Annane showed a 28-day mortality benefit when hydrocortisone was combined with fludrocortisone in a subgroup of patients whose adrenal glands were not responding adequately to the stress of sepsis. Six years later, the CORTICUS trial directly contradicted Annane’s findings, showing no mortality benefit from hydrocortisone, though it did find faster resolution of shock. The medical community was left with two well-designed trials pointing in opposite directions, a situation that is maddening for clinicians and terrifying for patients’ families trying to understand what their loved one is being given and why.
The contradiction persisted into 2018, when two more major trials landed almost simultaneously. The ADRENAL trial, enrolling 3,800 patients, found no significant difference in 90-day mortality with hydrocortisone, though it did shorten the duration of both shock and mechanical ventilation. The APROCCHSS trial, with 1,241 patients, showed a 90-day mortality benefit using hydrocortisone plus fludrocortisone. Today, the Surviving Sepsis Campaign guidelines recommend hydrocortisone only as a weak recommendation, rated Level 2C, reserved for patients who are not achieving hemodynamic stability despite adequate fluids and vasopressors. For families of dementia patients in the ICU, this means steroids may or may not be part of the treatment plan depending on how the patient responds to first-line therapies. If a clinician recommends adding hydrocortisone, it is reasonable to ask which evidence they are relying on, because the honest answer is that the evidence supports it in some circumstances but not others, and the medical community has been arguing about which circumstances for decades.
Vasopressin as a Septic Shock Treatment and What Recent Evidence Shows
Vasopressin, a hormone that constricts blood vessels and is produced naturally by the body, entered the septic shock conversation as a potential alternative or supplement to norepinephrine, the standard first-line vasopressor. The landmark VASST trial found that low-dose vasopressin did not reduce overall mortality compared to norepinephrine alone. However, a subgroup analysis suggested a possible benefit in patients with less severe septic shock, where mortality was 26.5 percent with vasopressin versus 35.7 percent with norepinephrine alone, a difference that just barely reached statistical significance at P equals 0.05. Subgroup analyses are notoriously unreliable, though, and this finding has never been confirmed in a dedicated trial. The debate has continued into 2025 and 2026 with new but still inconclusive data.
A 2025 analysis using artificial intelligence methods suggested that adding vasopressin to norepinephrine earlier in the course of septic shock could save lives and prevent renal failure, but this has not been validated in randomized controlled trials, which remain the gold standard. A 2025 meta-analysis found that early vasopressin may reduce hospital length of stay but does not improve mortality. A review article published in Critical Care in 2025, titled “Vasopressin and its analogues in patients with septic shock: holy Grail or unfulfilled promise?” captures the persistent uncertainty neatly. Current Surviving Sepsis Campaign guidelines position vasopressin as a second-line agent, to be added to norepinephrine when doses exceed 0.25 to 0.50 micrograms per kilogram per minute, not as a replacement for it. For older adults with dementia who develop septic shock, the choice between vasopressors is typically made by the ICU team based on the patient’s hemodynamic response, kidney function, and cardiac status. Families should understand that while vasopressin is a legitimate and widely used tool, its role remains a matter of active debate, and no one should present it as a settled question.
What a Drug Shortage Revealed About the Fragility of Septic Shock Care
In 2011, the same year Xigris was withdrawn, the United States experienced a shortage of norepinephrine, the frontline vasopressor that nearly every septic shock patient receives. The consequences were stark and measurable. A study published in association with the American Hospital Association found that hospitals affected by the shortage experienced a 3.7 percent higher in-hospital mortality rate among septic shock patients compared to hospitals that maintained adequate supply. That number represents real people who died not because medicine lacked the knowledge to treat them, but because the supply chain failed to deliver a generic drug that costs a fraction of what Xigris did. This episode is a sobering reminder that the biggest threats in septic shock treatment are not always about whether a specific drug works.
Sometimes the danger lies in whether the drugs that do work are actually available when a patient needs them. For families of dementia patients living in long-term care facilities, this has practical implications. It is worth asking whether the facility has a transfer agreement with a hospital that maintains robust ICU capabilities and drug supplies, because when sepsis strikes, the window for effective treatment is measured in hours, not days. The 2011 shortage also illustrates a broader vulnerability. When a drug as basic as norepinephrine can become scarce due to manufacturing disruptions, the entire infrastructure of critical care becomes fragile in ways that are invisible until a crisis hits.
Why Dementia Patients Face Elevated Sepsis Risk
Older adults with dementia are disproportionately vulnerable to sepsis for reasons that compound on each other. Cognitive decline makes it difficult or impossible for patients to report early symptoms like pain, fever, or confusion, meaning infections often progress further before they are detected. Many dementia patients require urinary catheters, which are a well-documented source of urinary tract infections that can escalate to sepsis. Immobility increases the risk of pressure wounds that become infected.
Swallowing difficulties raise the likelihood of aspiration pneumonia. And the immune system itself weakens with age, particularly in the context of the chronic neuroinflammation associated with Alzheimer’s disease and related dementias. When a dementia patient develops septic shock, the treatment decisions become even more complex because of the need to weigh aggressive ICU interventions against the patient’s overall prognosis and previously expressed wishes. Families who have had advance care planning conversations and documented preferences in a living will or POLST form are far better positioned to navigate these decisions than those who are confronting them for the first time in a hospital hallway at two in the morning.
Where Septic Shock Treatment Is Heading
The failure of Xigris and the ongoing uncertainty around steroids and vasopressin have pushed sepsis research in new directions. Rather than searching for a single breakthrough drug, the field is increasingly focused on precision approaches: identifying which patients will respond to which treatments based on biomarkers, genetic profiles, and real-time physiological data. The 2025 AI-driven analysis suggesting earlier vasopressin use is one example of this trend, using machine learning to identify treatment patterns associated with better outcomes in large datasets, even if the findings still require validation through traditional clinical trials.
There is also growing recognition that the non-pharmacological aspects of sepsis care, including early recognition, rapid antibiotic administration, and aggressive fluid resuscitation, may matter more than any single drug. For dementia caregivers, this reinforces the importance of vigilance. Knowing the early signs of infection, maintaining good communication with healthcare providers, and ensuring that care facilities have protocols for rapid sepsis screening can be more protective than any medication that may or may not be available or effective when the crisis arrives.
Conclusion
The story of Xigris is a story about the distance between hope and evidence. A drug that was supposed to save hundreds of thousands of lives turned out to save none, while exposing patients to bleeding risks and costing the healthcare system billions of dollars over a decade. The ongoing debates around corticosteroids and vasopressin in septic shock are less dramatic but no less important, reflecting a medical community that is still searching for reliable answers to one of the most lethal conditions in hospital medicine. For families caring for loved ones with dementia, these uncertainties are not abstract. They play out in real ICU rooms, with real consequences.
What families can do is prepare. Advance care planning conversations should happen before a crisis, not during one. Understanding that sepsis treatment relies heavily on supportive care, rapid antibiotics, and vasopressors rather than on any single miracle drug helps set realistic expectations. And asking questions of the medical team, including what evidence supports a particular treatment decision, is not only appropriate but essential. The history of septic shock treatment teaches us that even FDA-approved therapies can fail, that drug supply chains can break, and that the best defense remains early detection and honest, evidence-based care.
Frequently Asked Questions
What is sepsis, and why is it so dangerous for people with dementia?
Sepsis is the body’s overwhelming and life-threatening response to an infection, which can lead to organ failure and death. People with dementia face elevated risk because they often cannot communicate early symptoms, are more prone to infections from catheters and immobility, and have weakened immune responses. Sepsis kills more than 200,000 Americans annually, making it one of the leading causes of hospital deaths.
What was Xigris, and why was it taken off the market?
Xigris (drotrecogin alfa) was a recombinant form of human activated protein C manufactured by Eli Lilly. It was the only FDA-approved drug for severe sepsis, approved in 2001 despite a tied 10-to-10 advisory committee vote. It was withdrawn worldwide on October 25, 2011, after the PROWESS-SHOCK confirmatory trial showed no survival benefit for patients with septic shock.
Are steroids used to treat septic shock?
Hydrocortisone is sometimes used in septic shock, but only as a weak recommendation for patients who do not stabilize with fluids and vasopressors. Major trials have produced contradictory results over decades, with some showing mortality benefits and others showing none. Current guidelines reserve steroids for refractory cases.
What is the first-line drug treatment for septic shock today?
Norepinephrine is the standard first-line vasopressor for septic shock, used alongside rapid antibiotic administration and intravenous fluids. Vasopressin may be added as a second-line agent if norepinephrine doses become very high. There is currently no FDA-approved drug specifically targeting the sepsis inflammatory cascade.
How can families of dementia patients prepare for a potential sepsis emergency?
Families should complete advance care planning documents including a living will or POLST form, learn the early signs of infection such as fever, confusion, rapid breathing, and reduced urine output, and ensure their loved one’s care facility has protocols for rapid sepsis screening and transfer agreements with hospitals that have robust ICU capabilities.
